{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:07:38Z","timestamp":1793891258333,"version":"4.8.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioMed Eng OnLine"],"DOI":"10.1186\/s12938-024-01322-z","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:38:53Z","timestamp":1734766733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity"],"prefix":"10.1186","volume":"23","author":[{"given":"Hadi","family":"Zare-Zardini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Taghi","family":"Hedayati-Goudarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sadeghian-Nodoushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Soltaninejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"4","key":"1322_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101591","volume":"48","author":"T Abdul-Rahman","year":"2023","unstructured":"Abdul-Rahman T, Dunham A, Huang H, Bukhari SMA, Mehta A, Awuah WA, et al. Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics. Curr Probl Cardiol. 2023;48(4): 101591.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"1322_CR2","first-page":"59","volume":"8","author":"M Florescu","year":"2013","unstructured":"Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica. 2013;8(1):59\u201367.","journal-title":"Maedica"},{"issue":"4","key":"1322_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.25122\/jml-2022-0322","volume":"16","author":"HA Al-Hussaniy","year":"2023","unstructured":"Al-Hussaniy HA, Alburghaif AH, Alkhafaje Z, Al-Zobaidy MAJ, Alkuraishy HM, Mostafa-Hedeab G, et al. Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs. J Med Life. 2023;16(4):491\u2013500.","journal-title":"J Med Life"},{"issue":"3","key":"1322_CR4","first-page":"66","volume":"9","author":"A Briasoulis","year":"2022","unstructured":"Briasoulis A, Chasouraki A, Sianis A, Panagiotou N, Kourek C. Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents. J Cardiovasc Dev Dis. 2022;9(3):66.","journal-title":"J Cardiovasc Dev Dis."},{"issue":"4","key":"1322_CR5","first-page":"1132","volume":"11","author":"TW Mudd Jr","year":"2021","unstructured":"Mudd TW Jr, Khalid M, Guddati AK. Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(4):1132\u201347.","journal-title":"Am J Cancer Res"},{"key":"1322_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","author":"MB Morelli","year":"2022","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.847012.","journal-title":"Front Cardiovasc Med."},{"issue":"9","key":"1322_CR7","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/jcm9092885","volume":"9","author":"D Trapani","year":"2020","unstructured":"Trapani D, Zagami P, Nicol\u00f2 E, Pravettoni G, Curigliano G. Management of cardiac toxicity induced by chemotherapy. J Clin Med. 2020;9(9):2885.","journal-title":"J Clin Med"},{"issue":"8","key":"1322_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/jjco\/hyx068","volume":"47","author":"K Tajiri","year":"2017","unstructured":"Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017;47(8):678\u201382.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"1322_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"1322_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jgr.2020.02.004","volume":"45","author":"ZA Ratan","year":"2021","unstructured":"Ratan ZA, Haidere MF, Hong YH, Park SH, Lee JO, Lee J, et al. Pharmacological potential of ginseng and its major component ginsenosides. J Ginseng Res. 2021;45(2):199\u2013210.","journal-title":"J Ginseng Res"},{"issue":"7","key":"1322_CR11","first-page":"526","volume":"18","author":"M Tian","year":"2020","unstructured":"Tian M, Li LN, Zheng RR, Yang L, Wang ZT. Advances on hormone-like activity of Panax ginseng and ginsenosides. Chin J Nat Med. 2020;18(7):526\u201335.","journal-title":"Chin J Nat Med"},{"issue":"1","key":"1322_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41598-017-18938-y","volume":"8","author":"H Zare-Zardini","year":"2018","unstructured":"Zare-Zardini H, Taheri-Kafrani A, Amiri A, Bordbar AK. New generation of drug delivery systems based on ginsenoside Rh2-Lysine- and Arginine-treated highly porous graphene for improving anticancer activity. Sci Rep. 2018;8(1):586.","journal-title":"Sci Rep"},{"key":"1322_CR13","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.2147\/DDDT.S261027","volume":"14","author":"H Zare-Zardini","year":"2020","unstructured":"Zare-Zardini H, Alemi A. Assessment of a new ginsenoside Rh2 nanoniosomal formulation for enhanced antitumor efficacy on prostate cancer: an in vitro study. Drug Design Dev Ther. 2020;14:3315\u201324.","journal-title":"Drug Design Dev Ther"},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jtice.2018.08.010","volume":"93","author":"H Zare-Zardini","year":"2018","unstructured":"Zare-Zardini H, Taheri-Kafrani A, Ordooei M, Amiri A, Karimi-Zarchi M. Evaluation of toxicity of functionalized graphene oxide with ginsenoside Rh2, lysine and arginine on blood cancer cells (K562), red blood cells, blood coagulation and cardiovascular tissue: In vitro and in vivo studies. J Taiwan Inst Chem Eng. 2018;93:70\u20138.","journal-title":"J Taiwan Inst Chem Eng"},{"issue":"5","key":"1322_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract. 2021;17(5):228\u201336.","journal-title":"JCO Oncol Pract"},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-016-0730-0","volume":"18","author":"F Viganego","year":"2016","unstructured":"Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18:1\u201311.","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"1322_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/life12071034","volume":"12","author":"MC Badescu","year":"2022","unstructured":"Badescu MC, Badulescu OV, Scripcariu DV, Butnariu LI, Bararu-Bojan I, Popescu D, et al. Myocardial ischemia related to common cancer therapy-prevention insights. Life. 2022;12(7):1034.","journal-title":"Life"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amjcard.2020.12.092","volume":"145","author":"J Chahine","year":"2021","unstructured":"Chahine J, Shekhar S, Mahalwar G, Imazio M, Collier P, Klein A. Pericardial involvement in cancer. Am J Cardiol. 2021;145:151\u20139.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1322_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11936-018-0654-7","volume":"20","author":"AK Ghosh","year":"2018","unstructured":"Ghosh AK, Crake T, Manisty C, Westwood M. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018;20(7):60.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"7","key":"1322_CR20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32(7):852\u201362.","journal-title":"Can J Cardiol"},{"issue":"4","key":"1322_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.14797\/mdcj-15-4-267","volume":"15","author":"MS Avila","year":"2019","unstructured":"Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and treatment of chemotherapy-induced cardiotoxicity. Methodist Debakey Cardiovasc J. 2019;15(4):267\u201373.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"1322_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/795602","volume":"2015","author":"P Angsutararux","year":"2015","unstructured":"Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev. 2015;2015: 795602.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"1322_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jgo.2017.04.001","volume":"8","author":"P Reddy","year":"2017","unstructured":"Reddy P, Shenoy C, Blaes AH. Cardio-oncology in the older adult. J Geriatr Oncol. 2017;8(4):308\u201314.","journal-title":"J Geriatr Oncol"},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tro-21-34","volume":"6","author":"D-W Liu","year":"2022","unstructured":"Liu D-W, Fu Y-R, Liu S-H, Chen MY-C, Hsu R-J, Hsu W-L. The risk of cardiovascular toxicity caused by cancer radiotherapy\u2014a narrative review. Ther Radiol Oncol. 2022;6:4.","journal-title":"Ther Radiol Oncol."},{"key":"1322_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.713694","author":"A Montisci","year":"2021","unstructured":"Montisci A, Palmieri V, Liu JE, Vietri MT, Cirri S, Donatelli F, et al. Severe cardiac toxicity induced by cancer therapies requiring intensive care unit admission. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.713694.","journal-title":"Front Cardiovasc Med."},{"key":"1322_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.912329","volume":"9","author":"W Huang","year":"2022","unstructured":"Huang W, Xu R, Zhou B, Lin C, Guo Y, Xu H, et al. Clinical manifestations, monitoring, and prognosis: a review of cardiotoxicity after antitumor strategy. Front Cardiovasc Med. 2022;9: 912329.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"1322_CR27","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.21037\/tcr-20-1869","volume":"9","author":"H Dong","year":"2020","unstructured":"Dong H, Yao L, Wang M, Wang M, Li X, Sun X, et al. Can ACEI\/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?\u2014a meta-analysis of randomized controlled trials. Transl Cancer Res. 2020;9(11):7034\u201343.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"1322_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review. JACC CardioOncology. 2022;4(1):19\u201337.","journal-title":"JACC CardioOncology"},{"issue":"3","key":"1322_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41569-021-00611-7","volume":"19","author":"RS Taylor","year":"2022","unstructured":"Taylor RS, Dalal HM. The role of cardiac rehabilitation in improving cardiovascular outcomes. Nat Rev Cardiol. 2022;19(3):180\u201394.","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"1322_CR30","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.12998\/wjcc.v9.i8.1761","volume":"9","author":"P Winnige","year":"2021","unstructured":"Winnige P, Vysoky R, Dosbaba F, Batalik L. Cardiac rehabilitation and its essential role in the secondary prevention of cardiovascular diseases. World J Clin Cases. 2021;9(8):1761\u201384.","journal-title":"World J Clin Cases"},{"issue":"8","key":"1322_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cjca.2014.04.029","volume":"30","author":"J Truong","year":"2014","unstructured":"Truong J, Yan AT, Cramarossa G, Chan KK. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol. 2014;30(8):869\u201378.","journal-title":"Can J Cardiol"},{"issue":"7","key":"1322_CR32","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1089\/ars.2020.8055","volume":"34","author":"C Cadeddu Dessalvi","year":"2021","unstructured":"Cadeddu Dessalvi C, Deidda M, Noto A, Madeddu C, Cugusi L, Santoro C, et al. Antioxidant approach as a cardioprotective strategy in chemotherapy-induced cardiotoxicity. Antioxid Redox Signal. 2021;34(7):572\u201388.","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"1322_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.58803\/rbes.v2i2.14","volume":"2","author":"H Kazemian","year":"2023","unstructured":"Kazemian H, Mehrad-Majd H. Recent advances in the prevention and treatment of chemotherapy\u2013induced cardiotoxicity. Res Biotechnol Environ Sci. 2023;2(2):24\u20139.","journal-title":"Res Biotechnol Environ Sci"},{"key":"1322_CR34","doi-asserted-by":"publisher","DOI":"10.18502\/ijpho.v12i1.8356","author":"SD Farhangfar","year":"2022","unstructured":"Farhangfar SD, Fesahat F, Miresmaeili SM, Zare-Zardini H. Evaluating the blood toxicity of functionalized graphene-arginine with anticancer drug ginsenoside Rh2 in balb\/c mouse model with breast cancer. Iranian J Pediatr Hematol Oncol. 2022. https:\/\/doi.org\/10.18502\/ijpho.v12i1.8356.","journal-title":"Iranian J Pediatr Hematol Oncol."},{"issue":"12","key":"1322_CR35","first-page":"1442","volume":"25","author":"SD Farhangfar","year":"2022","unstructured":"Farhangfar SD, Fesahat F, Zare-Zardini H, Dehghan-Manshadi M, Zare F, Miresmaeili SM, et al. In vivo study of anticancer activity of ginsenoside Rh2-containing arginine-reduced graphene in a mouse model of breast cancer. Iran J Basic Med Sci. 2022;25(12):1442\u201351.","journal-title":"Iran J Basic Med Sci"},{"issue":"13","key":"1322_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3390\/molecules24132443","volume":"24","author":"Z-Y Shi","year":"2019","unstructured":"Shi Z-Y, Zeng J-Z, Wong AST. Chemical structures and pharmacological profiles of ginseng saponins. Molecules. 2019;24(13):2443.","journal-title":"Molecules"},{"issue":"8","key":"1322_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.phytochem.2011.02.012","volume":"72","author":"LW Qi","year":"2011","unstructured":"Qi LW, Wang CZ, Yuan CS. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry. 2011;72(8):689\u201399.","journal-title":"Phytochemistry"},{"issue":"19","key":"1322_CR38","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.3390\/molecules25194390","volume":"25","author":"XM Piao","year":"2020","unstructured":"Piao XM, Huo Y, Kang JP, Mathiyalagan R. Diversity of ginsenoside profiles produced by various processing technologies. Molecules. 2020;25(19):4390.","journal-title":"Molecules"},{"issue":"7","key":"1322_CR39","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.3390\/ijms24076119","volume":"24","author":"WY Jang","year":"2023","unstructured":"Jang WY, Hwang JY, Cho JY. Ginsenosides from Panax ginseng as key modulators of NF-\u03baB signaling are powerful anti-inflammatory and anticancer agents. Int J Mol Sci. 2023;24(7):6119.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1322_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jgr.2021.07.007","volume":"46","author":"SH Hyun","year":"2022","unstructured":"Hyun SH, Bhilare KD, In G, Park CK, Kim JH. Effects of Panax ginseng and ginsenosides on oxidative stress and cardiovascular diseases: pharmacological and therapeutic roles. J Ginseng Res. 2022;46(1):33\u20138.","journal-title":"J Ginseng Res"},{"key":"1322_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2024.100480","volume":"12","author":"SA Parmar","year":"2024","unstructured":"Parmar SA, Mayasa V, Nelson VK, Divecha J. A systemic review of ginseng and its activity on coronary heart disease. Pharmacol Res Modern Chin Med. 2024;12: 100480.","journal-title":"Pharmacol Res Modern Chin Med"},{"key":"1322_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.688490","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Huang Q, Chen J, Qi H, Liu J, Chen Z, et al. Neuroprotective potentials of Panax ginseng against Alzheimer\u2019s disease: a review of preclinical and clinical evidences. Front Pharmacol. 2021;12: 688490.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1322_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jgr.2014.03.001","volume":"38","author":"CH Lee","year":"2014","unstructured":"Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res. 2014;38(3):161\u20136.","journal-title":"J Ginseng Res"},{"issue":"4","key":"1322_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.identj.2023.02.004","volume":"73","author":"Y Peng","year":"2023","unstructured":"Peng Y, Pan W, Cao X, Liu C. Potential oral health benefits of ginseng and its extracts. Int Dent J. 2023;73(4):473\u201380.","journal-title":"Int Dent J"},{"issue":"3","key":"1322_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jgr.2017.10.004","volume":"42","author":"JH Kim","year":"2018","unstructured":"Kim JH. Pharmacological and medical applications of Panax ginseng and ginsenosides: a review for use in cardiovascular diseases. J Ginseng Res. 2018;42(3):264\u20139.","journal-title":"J Ginseng Res"},{"key":"1322_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105481","volume":"166","author":"M Sarhene","year":"2021","unstructured":"Sarhene M, Ni JY, Duncan ES, Liu Z, Li S, Zhang J, et al. Ginsenosides for cardiovascular diseases; update on pre-clinical and clinical evidence, pharmacological effects and the mechanisms of action. Pharmacol Res. 2021;166: 105481.","journal-title":"Pharmacol Res"},{"key":"1322_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1271029","author":"M-M Tang","year":"2023","unstructured":"Tang M-M, Zhao S-T, Li R-Q, Hou W. Therapeutic mechanisms of ginseng in coronary heart disease. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1271029.","journal-title":"Front Pharmacol"},{"key":"1322_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1034870","author":"L Liu","year":"2022","unstructured":"Liu L, Hu J, Mao Q, Liu C, He H, Hui X, et al. Functional compounds of ginseng and ginseng-containing medicine for treating cardiovascular diseases. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.1034870.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1322_CR49","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3390\/app13052893","volume":"13","author":"MN Morshed","year":"2023","unstructured":"Morshed MN, Ahn JC, Mathiyalagan R, Rupa EJ, Akter R, Karim MR, et al. Antioxidant activity of Panax ginseng to regulate ROS in various chronic diseases. Appl Sci. 2023;13(5):2893.","journal-title":"Appl Sci"},{"issue":"3","key":"1322_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejphar.2006.01.001","volume":"532","author":"J-T Xie","year":"2006","unstructured":"Xie J-T, Shao Z-H, Vanden Hoek TL, Chang W-T, Li J, Mehendale S, et al. Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur J Pharmacol. 2006;532(3):201\u20137.","journal-title":"Eur J Pharmacol"},{"key":"1322_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1215020","author":"X Li","year":"2023","unstructured":"Li X, Cao D, Sun S, Wang Y. Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1215020.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1322_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5142\/jgr.2011.35.2.129","volume":"35","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Lee SG, Chae IG, Kim MJ, Im NK, Yu MH, et al. Antioxidant effects of fermented red ginseng extracts in streptozotocin-induced diabetic rats. J Ginseng Res. 2011;35(2):129\u201337.","journal-title":"J Ginseng Res"},{"issue":"23","key":"1322_CR53","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.3390\/cells11233843","volume":"11","author":"M Batty","year":"2022","unstructured":"Batty M, Bennett MR. The role of oxidative stress in atherosclerosis. Cells. 2022;11(23):3843.","journal-title":"Cells"},{"issue":"5","key":"1322_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/foods12050925","volume":"12","author":"H Kang","year":"2023","unstructured":"Kang H, Kim B. Bioactive compounds as inhibitors of inflammation, oxidative stress and metabolic dysfunctions via regulation of cellular redox balance and histone acetylation state. Foods. 2023;12(5):925.","journal-title":"Foods"},{"issue":"4","key":"1322_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5830\/CVJA-2011-068","volume":"23","author":"M Mudau","year":"2012","unstructured":"Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr. 2012;23(4):222\u201331.","journal-title":"Cardiovasc J Afr"},{"key":"1322_CR56","doi-asserted-by":"publisher","first-page":"1166898","DOI":"10.3389\/fphar.2023.1166898","volume":"14","author":"W Jin","year":"2023","unstructured":"Jin W, Li C, Yang S, Song S, Hou W, Song Y, et al. Hypolipidemic effect and molecular mechanism of ginsenosides: a review based on oxidative stress. Front Pharmacol. 2023;14:1166898.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1322_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jgr.2020.07.002","volume":"45","author":"Q Xue","year":"2021","unstructured":"Xue Q, He N, Wang Z, Fu X, Aung LHH, Liu Y, et al. Functional roles and mechanisms of ginsenosides from Panax ginseng in atherosclerosis. J Ginseng Res. 2021;45(1):22\u201331.","journal-title":"J Ginseng Res"},{"issue":"21","key":"1322_CR58","doi-asserted-by":"publisher","first-page":"12906","DOI":"10.3390\/ijms232112906","volume":"23","author":"MY Henein","year":"2022","unstructured":"Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022;23(21):12906.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1322_CR59","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/biom10030444","volume":"10","author":"DS Im","year":"2020","unstructured":"Im DS. Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of Panax ginseng. Biomolecules. 2020;10(3):444.","journal-title":"Biomolecules"},{"issue":"12","key":"1322_CR60","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/antiox10121972","volume":"10","author":"CH Ma","year":"2021","unstructured":"Ma CH, Chou WC, Wu CH, Jou IM, Tu YK, Hsieh PL, et al. Ginsenoside Rg3 attenuates TNF-\u03b1-induced damage in chondrocytes through regulating SIRT1-mediated anti-apoptotic and anti-inflammatory mechanisms. Antioxidants. 2021;10(12):1972.","journal-title":"Antioxidants"},{"issue":"6","key":"1322_CR61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jgr.2021.12.007","volume":"46","author":"L You","year":"2022","unstructured":"You L, Cha S, Kim M-Y, Cho JY. Ginsenosides are active ingredients in Panax ginseng with immunomodulatory properties from cellular to organismal levels. J Ginseng Res. 2022;46(6):711\u201321.","journal-title":"J Ginseng Res"},{"issue":"5","key":"1322_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255\u201365.","journal-title":"Nat Rev Cardiol"},{"key":"1322_CR63","doi-asserted-by":"publisher","first-page":"1022360","DOI":"10.3389\/fcvm.2023.1022360","volume":"10","author":"A Moini Jazani","year":"2023","unstructured":"Moini Jazani A, Arabzadeh A, Haghi-Aminjan H, Nasimi Doost Azgomi R. The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: a systematic review of non-clinical studies. Front Cardiovasc Med. 2023;10:1022360.","journal-title":"Front Cardiovasc Med."},{"issue":"6","key":"1322_CR64","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jgr.2021.03.001","volume":"45","author":"Y Wan","year":"2021","unstructured":"Wan Y, Wang J, Xu JF, Tang F, Chen L, Tan YZ, et al. Panax ginseng and its ginsenosides: potential candidates for the prevention and treatment of chemotherapy-induced side effects. J Ginseng Res. 2021;45(6):617\u201330.","journal-title":"J Ginseng Res"},{"key":"1322_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.945896","author":"J Zhao","year":"2022","unstructured":"Zhao J, Li M, Xu J, Cheng W. The modulation of ion channels in cancer chemo-resistance. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.945896.","journal-title":"Front Oncol"},{"issue":"1","key":"1322_CR66","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12906-022-03647-5","volume":"22","author":"AY Han","year":"2022","unstructured":"Han AY, Ha SM, Shin YK, Seol GH. Ginsenoside Rg-1 prevents elevated cytosolic Ca(2+) via store-operated Ca(2+) entry in high-glucose-stimulated vascular endothelial and smooth muscle cells. BMC Complem Med Ther. 2022;22(1):166.","journal-title":"BMC Complem Med Ther"},{"key":"1322_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1327033","author":"L Shi","year":"2024","unstructured":"Shi L, Luo J, Wei X, Xu X, Tu L. The protective role of ginsenoside Rg3 in heart diseases and mental disorders. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1327033.","journal-title":"Front Pharmacol"},{"key":"1322_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106765","volume":"192","author":"Z Yan","year":"2023","unstructured":"Yan Z, Zhong L, Zhu W, Chung SK, Hou P. Chinese herbal medicine for the treatment of cardiovascular diseases \u2500 targeting cardiac ion channels. Pharmacol Res. 2023;192: 106765.","journal-title":"Pharmacol Res"},{"key":"1322_CR69","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/506214","volume":"2012","author":"H Wang","year":"2012","unstructured":"Wang H, Yu P, Gou H, Zhang J, Zhu M, Wang Z, et al. Cardioprotective effects of 20(S)-Ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evid Based Complement Altern Med. 2012;2012: 506214.","journal-title":"Evid Based Complement Altern Med."},{"key":"1322_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2023.103256","volume":"56","author":"V Cecarini","year":"2023","unstructured":"Cecarini V, Cuccioloni M, Gong C, Liu Z, Bonfili L, Angeletti M, et al. Role of Panax ginseng and ginsenosides in regulating cholesterol homeostasis. Food Biosci. 2023;56: 103256.","journal-title":"Food Biosci"},{"issue":"6","key":"1322_CR71","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3390\/molecules27061903","volume":"27","author":"YS Jing","year":"2022","unstructured":"Jing YS, Ma YF, Pan FB, Li MS, Zheng YG, Wu LF, et al. An insight into antihyperlipidemic effects of polysaccharides from natural resources. Molecules. 2022;27(6):1903.","journal-title":"Molecules"},{"issue":"4","key":"1322_CR72","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jgr.2021.11.002","volume":"46","author":"B Kwon","year":"2022","unstructured":"Kwon B, Song Y, Kim JG, Lee D, Lee SH, Cho YK, et al. Preventive effects of ginseng against atherosclerosis and subsequent ischemic stroke: a randomized controlled trial (PEGASUS trial). J Ginseng Res. 2022;46(4):585\u201391.","journal-title":"J Ginseng Res"},{"key":"1322_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115715","volume":"300","author":"J Chen","year":"2023","unstructured":"Chen J, Huang Q, Li J, Yao Y, Sun W, Zhang Z, et al. Panax ginseng against myocardial ischemia\/reperfusion injury: a review of preclinical evidence and potential mechanisms. J Ethnopharmacol. 2023;300: 115715.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"1322_CR74","first-page":"14497","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Li J, Li Z. Ginsenoside Rd mitigates myocardial ischemia-reperfusion injury via Nrf2\/HO-1 signaling pathway. Int J Clin Exp Med. 2015;8(8):14497\u2013504.","journal-title":"Int J Clin Exp Med"},{"key":"1322_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116111","volume":"171","author":"Q Feng","year":"2024","unstructured":"Feng Q, Ling L, Yuan H, Guo Z, Ma J. Ginsenoside Rd: a promising target for ischemia-reperfusion injury therapy (a mini review). Biomed Pharmacother. 2024;171: 116111.","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"1322_CR76","doi-asserted-by":"publisher","first-page":"326","DOI":"10.21037\/atm.2017.06.27","volume":"5","author":"D Moris","year":"2017","unstructured":"Moris D, Spartalis M, Spartalis E, Karachaliou GS, Karaolanis GI, Tsourouflis G, et al. The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox. Ann Transl Med. 2017;5(16):326.","journal-title":"Ann Transl Med"},{"issue":"3","key":"1322_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.14744\/AnatolJCardiol.2023.3606","volume":"28","author":"Y Deng","year":"2024","unstructured":"Deng Y, Chen Q, Wang T, Wang S, Li R, Wang Y, et al. Myocardial ischemia\/reperfusion injury: mechanism and targeted treatment for ferroptosis. Anatol J Cardiol. 2024;28(3):133\u201341.","journal-title":"Anatol J Cardiol"},{"key":"1322_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154681","volume":"113","author":"J Ye","year":"2023","unstructured":"Ye J, Lyu T-J, Li L-Y, Liu Y, Zhang H, Wang X, et al. Ginsenoside Re attenuates myocardial ischemia\/reperfusion induced ferroptosis via miR-144-3p\/SLC7A11. Phytomedicine. 2023;113: 154681.","journal-title":"Phytomedicine"},{"issue":"1","key":"1322_CR79","doi-asserted-by":"publisher","first-page":"44579","DOI":"10.1038\/srep44579","volume":"7","author":"Y-C Cui","year":"2017","unstructured":"Cui Y-C, Pan C-S, Yan L, Li L, Hu B-H, Chang X, et al. Ginsenoside Rb1 protects against ischemia\/reperfusion-induced myocardial injury via energy metabolism regulation mediated by RhoA signaling pathway. Sci Rep. 2017;7(1):44579.","journal-title":"Sci Rep"},{"key":"1322_CR80","doi-asserted-by":"publisher","first-page":"6313625","DOI":"10.1155\/2017\/6313625","volume":"2017","author":"Q Zheng","year":"2017","unstructured":"Zheng Q, Bao X-Y, Zhu P-C, Tong Q, Zheng G-Q, Wang Y. Ginsenoside Rb1 for myocardial ischemia\/reperfusion injury: preclinical evidence and possible mechanisms. Oxid Med Cell Longev. 2017;2017:6313625.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"1322_CR81","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jgr.2021.05.010","volume":"46","author":"M Irfan","year":"2022","unstructured":"Irfan M, Lee YY, Lee KJ, Kim SD, Rhee MH. Comparative antiplatelet and antithrombotic effects of red ginseng and fermented red ginseng extracts. J Ginseng Res. 2022;46(3):387\u201395.","journal-title":"J Ginseng Res"},{"issue":"1","key":"1322_CR82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jgr.2019.05.005","volume":"44","author":"M Irfan","year":"2020","unstructured":"Irfan M, Kim M, Rhee MH. Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases. J Ginseng Res. 2020;44(1):24\u201332.","journal-title":"J Ginseng Res"},{"issue":"6","key":"1322_CR83","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jgr.2023.04.006","volume":"47","author":"H-W Kwon","year":"2023","unstructured":"Kwon H-W, Shin J-H, Rhee MH, Park C-E, Lee D-H. Anti-thrombotic effects of ginsenoside Rk3 by regulating cAMP and PI3K\/MAPK pathway on human platelets. J Ginseng Res. 2023;47(6):706\u201313.","journal-title":"J Ginseng Res"},{"issue":"1","key":"1322_CR84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1476-5381.2012.01967.x","volume":"167","author":"M Endale","year":"2012","unstructured":"Endale M, Lee W, Kamruzzaman S, Kim S, Park J, Park M, et al. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. Br J Pharmacol. 2012;167(1):109\u201327.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1322_CR85","first-page":"102","volume":"24","author":"JW Liu","year":"2003","unstructured":"Liu JW, Wei DZ, Du CB, Zhong JJ. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2. Acta Pharmacol Sin. 2003;24(2):102\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"1322_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.vph.2018.06.002","volume":"109","author":"M Irfan","year":"2018","unstructured":"Irfan M, Jeong D, Kwon H-W, Shin J-H, Park S-J, Kwak D, et al. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling. Vascul Pharmacol. 2018;109:45\u201355.","journal-title":"Vascul Pharmacol"},{"key":"1322_CR87","first-page":"7125162","volume":"2019","author":"K Kim","year":"2019","unstructured":"Kim K, Park K-I. A review of antiplatelet activity of traditional medicinal herbs on integrative medicine studies. Evid Based Complement Altern Med. 2019;2019:7125162.","journal-title":"Evid Based Complement Altern Med"},{"issue":"1","key":"1322_CR88","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.thromres.2013.10.032","volume":"133","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Jiang L, Xu C, Luo D, Zeng C, Liu P, et al. Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res. 2014;133(1):57\u201365.","journal-title":"Thromb Res"},{"issue":"7","key":"1322_CR89","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2459\/JCM.0000000000000667","volume":"19","author":"CC Dessalvi","year":"2018","unstructured":"Dessalvi CC, Deidda M, Mele D, Bassareo PP, Esposito R, Santoro C, et al. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. J Cardiovasc Med. 2018;19(7):315\u201323.","journal-title":"J Cardiovasc Med"},{"issue":"1","key":"1322_CR90","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/FJC.0b013e31828f8d45","volume":"62","author":"YJ Zhang","year":"2013","unstructured":"Zhang YJ, Zhang XL, Li MH, Iqbal J, Bourantas CV, Li JJ, et al. The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J Cardiovasc Pharmacol. 2013;62(1):50\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"1322_CR91","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.taap.2015.06.014","volume":"287","author":"HH Kwok","year":"2015","unstructured":"Kwok HH, Chan LS, Poon PY, Yue PY, Wong RN. Ginsenoside-Rg1 induces angiogenesis by the inverse regulation of MET tyrosine kinase receptor expression through miR-23a. Toxicol Appl Pharmacol. 2015;287(3):276\u201383.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"1322_CR92","doi-asserted-by":"publisher","first-page":"6701","DOI":"10.1007\/s11033-022-07270-y","volume":"49","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Balaei N, Shoorei H, Hasan SMF, Hussen BM, Talebi SF, et al. The effects of Ginsenosides on PI3K\/AKT signaling pathway. Mol Biol Rep. 2022;49(7):6701\u201316.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"1322_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08354","volume":"7","author":"E-SA Arafa","year":"2021","unstructured":"Arafa E-SA, Refaey MS, Abd El-Ghafar OA, Hassanein EH, Sayed AM. The promising therapeutic potentials of ginsenosides mediated through p38 MAPK signaling inhibition. Heliyon. 2021;7(11): e08354.","journal-title":"Heliyon."},{"key":"1322_CR94","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jep.2016.01.022","volume":"181","author":"B-R Yang","year":"2016","unstructured":"Yang B-R, Cheung K-K, Zhou X, Xie R-F, Cheng P-P, Wu S, et al. Amelioration of acute myocardial infarction by saponins from flower buds of Panax notoginseng via pro-angiogenesis and anti-apoptosis. J Ethnopharmacol. 2016;181:50\u20138.","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"1322_CR95","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/CIRCULATIONAHA.105.535294","volume":"112","author":"R Khurana","year":"2005","unstructured":"Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease. Circulation. 2005;112(12):1813\u201324.","journal-title":"Circulation"},{"issue":"4","key":"1322_CR96","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ejps.2009.08.008","volume":"38","author":"L-S Chan","year":"2009","unstructured":"Chan L-S, Yue PYK, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur J Pharm Sci. 2009;38(4):370\u20137.","journal-title":"Eur J Pharm Sci"},{"key":"1322_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149910","volume":"710","author":"Y Zhai","year":"2024","unstructured":"Zhai Y, Bai J, Peng Y, Cao J, Fang G, Dong Y, et al. Ginsenoside Rb1 attenuates doxorubicin induced cardiotoxicity by suppressing autophagy and ferroptosis. Biochem Biophys Res Commun. 2024;710: 149910.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1322_CR98","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4062\/biomolther.2016.066","volume":"25","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wang Y, Ma Z, Liang Q, Tang X, Tan H, et al. Ginsenoside Rb1 inhibits doxorubicin-triggered H9C2 cell apoptosis via aryl hydrocarbon receptor. Biomol Ther. 2016;25(2):202.","journal-title":"Biomol Ther"},{"issue":"11","key":"1322_CR99","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.3390\/ijms19113658","volume":"19","author":"Z-M Xu","year":"2018","unstructured":"Xu Z-M, Li C-B, Liu Q-L, Li P, Yang H. Ginsenoside Rg1 prevents doxorubicin-induced cardiotoxicity through the inhibition of autophagy and endoplasmic reticulum stress in mice. Int J Mol Sci. 2018;19(11):3658.","journal-title":"Int J Mol Sci"},{"issue":"48","key":"1322_CR100","doi-asserted-by":"publisher","first-page":"83792","DOI":"10.18632\/oncotarget.19698","volume":"8","author":"C Zhu","year":"2017","unstructured":"Zhu C, Wang Y, Liu H, Mu H, Lu Y, Zhang J, et al. Oral administration of Ginsenoside Rg1 prevents cardiac toxicity induced by doxorubicin in mice through anti-apoptosis. Oncotarget. 2017;8(48):83792.","journal-title":"Oncotarget"},{"issue":"3","key":"1322_CR101","first-page":"433","volume":"32","author":"B Qiu","year":"2022","unstructured":"Qiu B, Mao M, Ma Z, Deng B, Shen L, Zhou D, et al. Ginsenoside Rg2 attenuates doxorubicin-induced cardiomyocyte apoptosis via the PI3K\/Akt pathway. Rev Bras. 2022;32(3):433\u20139.","journal-title":"Rev Bras"},{"issue":"6","key":"1322_CR102","first-page":"825","volume":"78","author":"Y Pi","year":"2021","unstructured":"Pi Y, Chen X, Zhang X, Cai H. Ginsenoside RB1 alleviates ADR-induced H9c2 cell injury by regulating MIR-130B. Acta Pol Pharm. 2021;78(6):825.","journal-title":"Acta Pol Pharm"},{"issue":"6","key":"1322_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13246","volume":"55","author":"J Hou","year":"2022","unstructured":"Hou J, Yun Y, Cui C, Kim S. Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice. Cell Prolif. 2022;55(6): e13246.","journal-title":"Cell Prolif"}],"container-title":["BioMedical Engineering OnLine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-024-01322-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12938-024-01322-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-024-01322-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T09:03:54Z","timestamp":1734771834000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomedical-engineering-online.biomedcentral.com\/articles\/10.1186\/s12938-024-01322-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1186\/s12938-024-01322-z","relation":{},"ISSN":["1475-925X"],"issn-type":[{"value":"1475-925X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}